Domperidone was previously approved by FDA but was recently removed from the market in the US because of its potential harmful effect on children when it is used for increasing lactation by increasing prolactin levels and its association with risk of cardiac arrhythmia in older patients. Here, PRL is linked to chronic obstructive pulmonary disease.